Key features and details
- Rat monoclonal [RA3-6B2] to CD45R (APC/Cy7®)
- Suitable for: Flow Cyt
- Reacts with: Mouse, Human
- Conjugation: APC/Cy7®. Ex: 650nm, Em: 774nm
- Isotype: IgG2a
Product nameAnti-CD45R antibody [RA3-6B2] (APC/Cy7®)
See all CD45R primary antibodies
DescriptionRat monoclonal [RA3-6B2] to CD45R (APC/Cy7®)
ConjugationAPC/Cy7®. Ex: 650nm, Em: 774nm
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Mouse, Human
Abelson murine leukemia virus-induced pre-B tumor cells
- Cells from murine mesenteric lymph nodes.
General notesThis product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferpH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.14% Monobasic dihydrogen sodium phosphate, 0.87% Sodium chloride, 0.1% Gelatin
Concentration information loading...
Purification notesPurified from TCS
Light chain typekappa
- Anti-CD45R antibody [RA3-6B2] (PerCP/Cy5.5®) (ab210342)
- Anti-CD45R antibody [RA3-6B2] (FITC) (ab234244)
- Anti-CD45 antibody [RA3-6B2] (redFluor™ 710) (ab242264)
- Anti-CD45R antibody [RA3-6B2] (FITC) (ab24897)
- Anti-CD45R antibody [RA3-6B2] (violetFluor™ 450) (ab253061)
- Anti-CD45R antibody [RA3-6B2] (ab64100)
Our Abpromise guarantee covers the use of ab79107 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use at an assay dependent concentration.|
FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains.
DomainThe first PTPase domain interacts with SKAP1.
modificationsHeavily N- and O-glycosylated.
Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
- Information by UniProt
- B220 antibody
- CD45 antibody
- CD45 antigen antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab79107 has not yet been referenced specifically in any publications.